Literature DB >> 2223572

Modification of the 31P magnetic resonance spectra of a rat tumour using vasodilators and its relationship to hypotension.

G M Tozer1, R J Maxwell, J R Griffiths, P Pham.   

Abstract

The effects of different doses of hydralazine and prostacyclin on the 31P magnetic resonance spectra of the LBDS1 fibrosarcoma were investigated and related to their effects on mean arterial blood pressure (MABP) and heart rate. The effect of reducing MABP by bleeding the animals, via the tail artery, was also investigated. Tumour spectral changes following high dose drug treatment (an increase in inorganic phosphate, a reduction in nucleotide triphosphates and a reduction in pH) were consistent with nutrient deprivation. These changes were dose dependent. Changes in MABP and heart rate were consistent with vasodilatation in normal tissues. However, for the same fall in MABP, hydralazine produced a greater rise in tumour inorganic phosphate (Pi) and a greater fall in tumour pH than did prostacyclin. Controlled bleeding was effective in reducing MABP. It also reduced tumour pH but had no significant effect on tumour Pi. The clinical application of the two drugs for reducing tumour blood flow and pH for therapy is likely to be limited by the large degree of hypotension necessary to produce an effect. The differential effect of the two drugs for the same fall in MABP may be related to different degrees of direct tumour vasodilatation or to a direct effect of hydralazine on tumour energy metabolism. The observation that controlled bleeding does not change tumour Pi is further evidence indicating that the degree of arterial hypotension is not the sole factor in determining tumour energy status.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2223572      PMCID: PMC1971474          DOI: 10.1038/bjc.1990.329

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  27 in total

1.  Cardiovascular actions of prostacyclin (PCI2) in chloralose anaesthetized dogs [proceedings].

Authors:  J M Armstrong; D Chapple; G J Dusting; R Hughes; S Moncada; J R Vane
Journal:  Br J Pharmacol       Date:  1977-09       Impact factor: 8.739

Review 2.  Clinical pharmacology and potential of prostacyclin.

Authors:  P J Lewis; C T Dollery
Journal:  Br Med Bull       Date:  1983-07       Impact factor: 4.291

3.  Stability of prostacyclin in human plasma and whole blood: studies on the protective effect of albumin.

Authors:  M A Orchard; C Robinson
Journal:  Thromb Haemost       Date:  1981-10       Impact factor: 5.249

4.  The angio-architecture of rat tumours.

Authors:  P Falk
Journal:  Bibl Anat       Date:  1977

5.  The effect of hydralazine on the tumor cytotoxicity of the hypoxic cell cytotoxin RSU-1069: evidence for therapeutic gain.

Authors:  D J Chaplin; B Acker
Journal:  Int J Radiat Oncol Biol Phys       Date:  1987-04       Impact factor: 7.038

6.  Abnormal response of tumor vasculature to vasoactive drugs.

Authors:  R C Chan; C F Babbs; R J Vetter; C H Lamar
Journal:  J Natl Cancer Inst       Date:  1984-01       Impact factor: 13.506

7.  Interstitial fluid pressure in DMBA-induced rat mammary tumours.

Authors:  H Wiig; E Tveit; R Hultborn; R K Reed; L Weiss
Journal:  Scand J Clin Lab Invest       Date:  1982-04       Impact factor: 1.713

Review 8.  Chemical modification of tumour blood flow.

Authors:  R L Jirtle
Journal:  Int J Hyperthermia       Date:  1988 Jul-Aug       Impact factor: 3.914

9.  Effects of intravenous infusion of prostacyclin (PGI2) in man.

Authors:  J O'Grady; S Warrington; M J Moti; S Bunting; R Flower; A S Fowle; E A Higgs; S Moncada
Journal:  Prostaglandins       Date:  1980-02

10.  Hydralazine-enhanced selective heating of transmissible venereal tumor implants in dogs.

Authors:  W D Voorhees; C F Babbs
Journal:  Eur J Cancer Clin Oncol       Date:  1982-10
View more
  9 in total

1.  Molecular Imaging of Cancer: Applications of Magnetic Resonance Methods.

Authors:  Barjor Gimi; Arvind P Pathak; Ellen Ackerstaff; Kristine Glunde; Dmitri Artemov; Zaver M Bhujwalla
Journal:  Proc IEEE Inst Electr Electron Eng       Date:  2005-04-01       Impact factor: 10.961

2.  Radiofrequency ablation: post-ablation assessment using CT perfusion with pharmacological modulation in a rat subcutaneous tumor model.

Authors:  Hanping Wu; Agata A Exner; Tianyi M Krupka; Brent D Weinberg; Ravi Patel; John R Haaga
Journal:  Acad Radiol       Date:  2009-03       Impact factor: 3.173

3.  Vasomodulation of tumor blood flow: effect on perfusion and thermal ablation size.

Authors:  Hanping Wu; Agata A Exner; Tianyi M Krupka; Brent D Weinberg; John R Haaga
Journal:  Ann Biomed Eng       Date:  2008-12-16       Impact factor: 3.934

4.  Effect of hydralazine in spontaneous tumours assessed by oxygen electrodes and 31P-magnetic resonance spectroscopy.

Authors:  M Nordsmark; R J Maxwell; P J Wood; I J Stratford; G E Adams; J Overgaard; M R Horsman
Journal:  Br J Cancer Suppl       Date:  1996-07

5.  Modification of tumour blood flow using the hypertensive agent, angiotensin II.

Authors:  G M Tozer; K M Shaffi
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

6.  Stable bioenergetic status despite substantial changes in blood flow and tissue oxygenation in a rat tumour.

Authors:  P Vaupel; D K Kelleher; T Engel
Journal:  Br J Cancer       Date:  1994-01       Impact factor: 7.640

7.  The potential for prazosin and calcitonin gene-related peptide (CGRP) in causing hypoxia in tumours.

Authors:  I A Burney; R J Maxwell; J R Griffiths; S B Field
Journal:  Br J Cancer       Date:  1991-10       Impact factor: 7.640

8.  31P-nuclear magnetic resonance spectroscopy in vivo of six human melanoma xenograft lines: tumour bioenergetic status and blood supply.

Authors:  H Lyng; D R Olsen; T E Southon; E K Rofstad
Journal:  Br J Cancer       Date:  1993-12       Impact factor: 7.640

9.  Direct evidence that hydralazine can induce hypoxia in both transplanted and spontaneous murine tumours.

Authors:  M R Horsman; M Nordsmark; M Høyer; J Overgaard
Journal:  Br J Cancer       Date:  1995-12       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.